ArticleERJ open research2023

A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.

Tom Wilkinson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.